| Literature DB >> 32760474 |
Aza Saijeva1, Gintaras Juodzbalys1,2.
Abstract
OBJECTIVES: The aim of this systematic review is to compare immediate implant placement in infected extraction sockets with non-infected extraction sockets in terms of implant survival and function.Entities:
Keywords: dental implantation; dental implants; infection; periapical granuloma; tooth socket
Year: 2020 PMID: 32760474 PMCID: PMC7393932 DOI: 10.5037/jomr.2020.11201
Source DB: PubMed Journal: J Oral Maxillofac Res ISSN: 2029-283X
PICO framework of the framed clinical question
| Definition | Description |
|---|---|
| Patients with infected sockets | |
| Immediate implant placement | |
| A control group with non-infected sockets | |
|
Implant success by evaluating: survival rate, marginal bone level, marginal gingival level, width of keratinized gingiva, modified | |
| What is the outcome of immediate implant placement in patients with infected sockets versus non-infected sockets with the evaluation of survival rate, marginal bone level, marginal gingival level, width of keratinized gingiva, modified bleeding index and probing depth? | |
Keywords used to conduct the literature search
| Concept | Keywords |
|---|---|
| "Infected socket*" OR "Periapical lesion*" OR "Endodontic lesion*" OR "Periodontal lesion*" OR "Radicular lesion*" OR "Periradicular lesion*" OR "Apical lesion*" OR "Apical pathology" OR "Periradicular pathology" OR "Radicular pathology" OR "Endodontic pathology" OR "Periapical pathology" OR "Apical pathological feature*" OR "Apical periodontitis" | |
| "Immediate implant*" OR "Fresh-socket* " OR "Fresh extraction*" OR ''Post-extraction" | |
First keyword terms and second keyword terms were combined with AND.
*truncation symbol.
Joanna Briggs Institute Critical Appraisal Checklist for Cohort Studies
| Question number | Defined question |
|---|---|
| Were the two groups similar and recruited from the same population? | |
| Were the exposures measured similarly to assign people to both exposed and unexposed groups? | |
| Was the exposure measured in a valid and reliable way? | |
| Were confounding factors identified? | |
| Were strategies to deal with confounding factors stated? | |
| Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | |
| Were the outcomes measured in a valid and reliable way? | |
| Was the follow-up time reported and sufficient to be long enough for outcomes to occur? | |
| Was follow-up complete, and if not, were the reasons to loss to follow-up described and explored? | |
| Were strategies to address incomplete follow up utilized? | |
| Was appropriate statistical analysis used? | |
Figure 1PRISMA flow diagram demonstrating the study selection.
Quality assessment of all the included cohort studies using the Joanna Briggs Institute Critical Appraisal Checklist for Cohort Studies
| Study |
Year of |
Study | Checklist | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | |||
| 2014 | Prospective | ? | + | + | - | - | + | + | + | + | N/A | + | |
| 2012 | Prospective | + | + | + | + | N/A | + | + | + | + | N/A | + | |
| 2010 | Prospective | + | + | + | N/A | N/A | + | + | + | + | N/A | + | |
| 2010 | Prospective | + | + | + | N/A | N/A | + | + | + | + | N/A | + | |
| 2016 | Prospective | + | + | + | N/A | N/A | + | + | + | + | N/A | + | |
| 2015 | Prospective | ? | + | + | - | - | + | + | + | + | N/A | + | |
| 2011 | Retrospective | + | + | + | + | + | + | + | + | + | N/A | + | |
| 2012 | Retrospective | + | + | + | N/A | N/A | + | + | + | + | N/A | + | |
| 2017 | Retrospective | ? | + | + | + | - | + | + | + | + | N/A | + | |
N/A = not applicable; ? = unclear; + = yes; - = no.
Characteristics of the included studies
| Study |
Patients |
Sockets | Smoking patients | IS pathology |
Age | Site |
Follow-up | Implant system |
|---|---|---|---|---|---|---|---|---|
| 18 | 36 (IS:18, NIS:18 | Included | Chronic periapical lesion | 18 - 50 | Incisors, canines and premolars | 36 | MIS C1 implants (MIS Implants Technologies Ltd.; Tel Aviv, Israel) | |
| 27 | 27 (IS:12, NIS:15) | Included | Periapical pathologies | 31 - 87 (IS) 28 - 82 (NIS) | Incisors, canines and premolars | 60 | Straumann® Standard Plus or Tapered Effect (Straumann AG; Basal, Switzerland) | |
| 37 | 275 (IS:197, NIS:78) |
Heavy smokers excluded | Chronic periodontal lesions | 32 - 71 | Incisors, canines and premolars | 48 | Sweden and Martina SPA, Due Carrare, Padova, Italy | |
| 30 | 30 (IS:15, NIS:15) |
Heavy smokers excluded | Periapical lesions and radiolucencies | 34 - 71 | Incisors, canines and premolars | 24 | Seven (Sweden and Martina SPA, Due Carrare, Padova, Italy) | |
| 60 | 168 (IS:66, NIS:102) | Non-smokers only | Chronic periapical lesions | 18 - 72 | Incisors, canines and premolars | 12 | Zimmer dental, USA | |
| 86 | 168 (IS:83, NIS:85) | No data | Acute and chronic infection | 26 - 77 | Incisors, canines and premolars | 12 | Leader Implants; Milan, Italy or and Bioner Sistemas Implantológicos, Barcelona, Spain | |
| 655 | 922 (IS:285, NIS:637) | Included | Chronic periapical lesion | Mean: 58.4 IS; 60.1 NIS | Incisors, canines, premolars and molars | 3 - 93 | Straumann® Tissue Level or Bone Level SLA (Straumann AG; Basal, Switzerland) | |
| 64 | 128 (IS:64, NIS:64) |
Heavy smokers excluded | Periapical pathologies | 21 - 71 | Incisors | 24 - 117 | No data | |
| 369 | 527 (IS:193, NIS:334) |
Heavy smokers included | Chronic infection | 22.8 - 81.9 | Incisors, canines, premolars and molars | Mean 52.1 |
BIOMET 3i® (BIOMET 3i LLC; Palm Beach Gardens, Florida, USA).
| |
n = numbers; IS = infected socket; NIS = non-infected socket; ASA = The American Society of Anaesthesiologists physical status classification system.
Details of the treatment procedures of the included studies
| Study |
Flap |
Granulation | Bone graft | Loading time |
Preoperative |
Preoperative |
Postoperative |
Postoperative |
|---|---|---|---|---|---|---|---|---|
| Flap | Removed | Xenograft | Delayed | Yes | No | Yes | Yes | |
| Flap | Removed | Xenograft | Delayed | No | No | Yes | Yes | |
| Flapless | Removed | None | Immediate | Yes | No | Yes | Yes | |
| Flapless | Removed | None | Delayed | Yes | No | Yes | Yes | |
| Flapless | Removed | None | Delayed | Yes | No | Yes | No | |
| Flapless | Removed | Xenograft | Immediate, early and delayed | Yes | No | No | No | |
| Flapless | Removed |
Autograft and/or xenograft | Delayed | Yes | Yes | No | No | |
| Flapless | Removed | Autograft or allograft or xenograft | Delayed | No | No | Yes | No | |
| Flapless or flap | Removed | Xenograft | Immediate, early and delayed | Yes | No | Yes | Yes | |
Data of the primary and secondary outcomes of the included studies
| Study |
Number of |
Failed implants |
Implant |
MBL |
MGL |
PD |
mBI |
WKG | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||||||||||||||
| IS | NIS | Total | IS | NIS | Total | IS | NIS | IS | NIS | IS | NIS | IS | NIS | IS | NIS | IS | NIS | |
| 18 | 18 | 36 | 1 | 0 | 1 | 94.4 | 100 |
1 years: 0.73 (0.22); |
1 years: 0.73 (0.29); |
1 years: 0.88 (0.75); |
1 years: 1.13 (0.23); |
1 years: 2.53 (0.44); |
1 years: 2.44 (0.28); |
1 years: 0.88 (0.75); |
1 years: 1.38 (0.84); |
1 years: 3.33 (1.08); |
1 years: 2.74 (0.73); | |
| 12 | 15 | 27 | 0 | 0 | 0 | 100 | 100 |
5 years: |
5 years: | N/D | N/D | N/D | 5 years: 3.3 (1.5) | 5 years: 3.7 (1.2) | ||||
| 197 | 78 | 275 | 2 | 0 | 2 | 98.9 | 100 |
1 years: 0.77 (0.39); |
1 years: 0.86 (0.47); | N/D | N/D | 4 years: 0.78 (0.23) | 4 years: 0.75 (0.39) | N/D | ||||
| 15 | 15 | 30 | 0 | 0 | 0 | 100 | 100 |
1 years: 0.83 (0.51); |
1 years: 0.80 (0.47); |
1 years: 0.16 (0.13); |
1 years: 0.21 (0.13); |
1 years: 1.8 (0.64); |
1 years: 1.85 (0.68); |
1 years: 0.69 (0.3); |
1 years: 0.68 (0.34); |
1 years: 3.64 (0.68); |
1 years: 3.68 (0.72); | |
| 66 | 102 | 168 | 6 | 2 | 8 | 90.8 | 98.1 | N/D | N/D | N/D | N/D | N/D | ||||||
| 83 | 85 | 168 | 2 | 1 | 3 | 97.6 | 98.8 | N/D | N/D | N/D | N/D | N/D | ||||||
| 285 | 637 | 922 | 7 | 8 | 15 | 97.5 | 98.7 | N/D | N/D | N/D | N/D | N/D | ||||||
| 64 | 64 | 128 | 1 | 1 | 2 | 98.1 | 98.2 | N/D | N/D | N/D | N/D | N/D | ||||||
| 193 | 334 | 527 | 3 | 7 | 10 | 98.4 (0.9) | 97.9 (0.8) | N/D | N/D | N/D | N/D | N/D | ||||||
MBL = marginal bone level; MGL = marginal gingival level changes; PD = probing depth; WKG = width of keratinized gingiva; mBI = modified bleeding index; IS = infected socket; NIS = non-infected socket; N/D = no data; SD = standard deviation; n = numbers.
Figure 2Implant survival rates of the included studies.
Figure 3Implant failure rates of the included studies.
Figure 4AMarginal bone level changes at the follow-up period of 1 year.
Figure 5AMarginal gingival level changes at the follow-up period of 1 year.
Figure 5BMarginal gingival level changes at the follow-up period of 2 years.
Figure 6AProbing depth changes of the included studies at the follow-up period of 1 year.
Figure 6BProbing depth changes of the included studies at the follow-up-period of 2 years.
Figure 7AModified bleeding index changes of the included studies at the follow-up period of 1 year.
Figure 8AWidth of keratinized gingiva of the included studies at the follow-up period of 1 year.
Figure 9Funnel plot demonstrating publication bias.
SE = standard error; RR = risk ratio.